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BACKGROUND
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of 
hospitalization for heart failure or death from cardiovascular causes among patients with 
heart failure and reduced ejection fraction. The effect of angiotensin receptor–neprily-
sin inhibition in patients with heart failure with preserved ejection fraction is unclear.
METHODS
We randomly assigned 4822 patients with New York Heart Association (NYHA) class II 
to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic pep-
tides, and structural heart disease to receive sacubitril–valsartan (target dose, 97 mg 
of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg 
twice daily). The primary outcome was a composite of total hospitalizations for heart 
failure and death from cardiovascular causes. Primary outcome components, second-
ary outcomes (including NYHA class change, worsening renal function, and change in 
Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 
0 to 100, with higher scores indicating fewer symptoms and physical limitations]), 
and safety were also assessed.
RESULTS
There were 894 primary events in 526 patients in the sacubitril–valsartan group and 1009 
primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence 
interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes 
was 8.5% in the sacubitril–valsartan group and 8.9% in the valsartan group (hazard 
ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart 
failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% 
of the patients in the sacubitril–valsartan group and in 12.6% of those in the valsartan 
group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, 
respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ 
clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the 
sacubitril–valsartan group. Patients in the sacubitril–valsartan group had a higher in-
cidence of hypotension and angioedema and a lower incidence of hyperkalemia. 
Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible 
benefit with sacubitril–valsartan in patients with lower ejection fraction and in women.
CONCLUSIONS
Sacubitril–valsartan did not result in a significantly lower rate of total hospitalizations 
for heart failure and death from cardiovascular causes among patients with heart failure 
and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF Clinical- 
Trials.gov number, NCT01920711.)
a bs tr ac t
Angiotensin–Neprilysin Inhibition in Heart Failure  
with Preserved Ejection Fraction
S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, 
B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, 
S.A. Boytsov, J. Comin-Colet, J. Cleland, H.-D. Düngen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, 
B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, and M.P. Lefkowitz,  
for the PARAGON-HF Investigators and Committees* 
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on February 11, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;17 nejm.org October 24, 20191610
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Heart failure with preserved ejec-tion fraction is common and is associat-ed with substantial morbidity and mortal-
ity.1 Several physiological mechanisms have been 
postulated, including myocardial hypertrophy and 
fibrosis,2 impaired diastolic compliance and re-
laxation,3 subclinical systolic dysfunction,4 and 
renal dysfunction leading to elevated intracardiac 
filling pressures, fluid retention, and exercise in-
tolerance. No therapy has convincingly reduced 
morbidity or mortality.5-8
The angiotensin receptor–neprilysin inhibitor 
sacubitril–valsartan resulted in a lower rate of hos-
pitalization for heart failure or death from cardio-
vascular causes than enalapril among patients 
with heart failure and reduced ejection fraction 
(≤40%).9 In patients with heart failure and pre-
served left ventricular ejection fraction, sacubitril–
valsartan resulted in a lower level of N-terminal 
pro–B-type natriuretic peptide (NT-proBNP), a 
larger reduction in left atrial size, and greater 
improvement in the New York Heart Association 
(NYHA) functional class than valsartan.10 We test-
ed whether sacubitril–valsartan would result in a 
lower rate of a composite outcome of total hospi-
talizations for heart failure and death from cardio-
vascular causes than valsartan.
Me thods
Trial Design and Oversight
The Prospective Comparison of ARNI [angiotensin 
receptor–neprilysin inhibitor] with ARB [angio-
tensin-receptor blockers] Global Outcomes in HF 
with Preserved Ejection Fraction (PARAGON-HF) 
trial was a randomized, double-blind, active-com-
parator trial.11 The steering committee designed 
and oversaw the conduct of the trial and data analy-
sis, in collaboration with the sponsor, Novartis. 
Ethics committee approval was provided at each 
trial center. An independent data and safety moni-
toring committee monitored trial conduct and 
patient safety. Data were collected, managed, and 
analyzed by the sponsor and corroborated by an 
independent academic statistician. The first draft 
of the manuscript was prepared by the first au-
thor, who had complete access to the data. All the 
authors made the decision to submit the manu-
script for publication and vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol, available with the 
full text of this article at NEJM.org.
Trial Patients
Eligibility requirements at screening included an 
age of 50 years or older, signs and symptoms of 
heart failure, NYHA class II to IV, an ejection 
fraction of 45% or higher within the previous 
6 months, elevated level of natriuretic peptides 
(with different cutoffs depending on the occur-
rence of recent hospitalization for heart failure 
and the presence of atrial fibrillation or flutter), 
evidence of structural heart disease, and diuretic 
therapy. Detailed inclusion and exclusion criteria 
are provided in Table S1 in the Supplementary 
Appendix, available at NEJM.org. All the patients 
provided written informed consent.
Trial Procedures
The trial consisted of a screening period, a single-
blind run-in period, and a double-blind treatment 
period (see the Supplementary Appendix). During 
the run-in period, all patients first received valsar-
tan at half the target dose, followed by sacubitril–
valsartan at half the target dose. Participants who 
had no unacceptable side effects in both run-in 
phases and whose laboratory values remained 
within prespecified safety criteria were randomly 
assigned in a 1:1 ratio to receive double-blind treat-
ment with either sacubitril–valsartan (target dose, 
97 mg of sacubitril with 103 mg of valsartan twice 
daily) or valsartan (target dose, 160 mg twice dai-
ly). Patients were evaluated at trial visits every 4 to 
16 weeks. Renin–angiotensin system inhibitors 
other than mineralocorticoid-receptor antagonists 
were discontinued before the run-in period, but all 
other background medications were continued. 
The dose of the trial drugs could be adjusted down 
if the target dose led to unacceptable side effects.
Trial Outcomes
The primary outcome was a composite of total 
(first and recurrent) hospitalizations for heart fail-
ure and death from cardiovascular causes. Sec-
ondary outcomes were the change from baseline 
to 8 months in the clinical summary score on 
the Kansas City Cardiomyopathy Questionnaire 
(KCCQ)12 (scores range from 0 to 100, with higher 
scores indicating fewer symptoms and physical 
limitations); the change from baseline to 8 months 
in NYHA class; the first occurrence of a decline 
in renal function (decrease in the estimated glo-
merular filtration rate of ≥50%, development of 
end-stage renal disease, or death due to renal fail-
ure) in a time-to-event analysis; and death from 
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any cause in a time-to-first-event analysis. All 
the outcomes except KCCQ score and NYHA 
class were blindly adjudicated according to pre-
specified criteria (Section 5 in the Supplemen-
tary Appendix). Hypotension, renal dysfunction, 
hyperkalemia, and angioedema were prespeci-
fied adverse events of interest; angioedema was 
adjudicated by a separate committee.
Statistical Analysis
We determined that 1847 primary events would 
provide the trial with 95% power to detect an 
overall 22% lower rate in the sacubitril–valsartan 
group (corresponding to a 30% lower risk of hos-
pitalization for heart failure and a 10% lower risk 
of death from cardiovascular causes) and at least 
80% power to detect an overall 19% lower rate 
(corresponding to a 25% lower risk of hospital-
ization for heart failure and a 10% lower risk of 
death from cardiovascular causes). We estimated 
that the target number of events would be ob-
tained by enrolling 4600 patients over a period 
of 29 months with a minimum follow-up of 26 
months, on the basis of an anticipated time-to-
first-primary-event rate of 9 events per 100 patient-
years.
The primary efficacy outcome was evaluated 
with the use of the semiparametric proportional 
rates method of Lin et al.13 and a joint gamma 
frailty model14 stratified according to geographic 
region. Ghosh–Lin and Kaplan–Meier curves were 
used to show the cumulative recurrent and first 
events, respectively. There was one interim anal-
ysis, with an adjusted alpha level of 0.048 for the 
final analysis. Several prespecified sensitivity anal-
yses of the primary outcome were also conducted, 
including other methods to analyze recurrent 
events, the addition of urgent heart-failure epi-
sodes that resulted in treatment but not hospital-
ization to the primary composite outcome, in-
vestigator-reported outcomes, and conventional 
time-to-first-event outcomes. We assessed the con-
sistency of the treatment effect among 12 pre-
specified subgroups that were analyzed individ-
ually and then in a multivariable model.
Analyses of the primary and secondary out-
comes were conducted according to the intention-
to-treat principle. If the primary outcome reached 
significance, a hierarchical, sequentially rejective 
procedure was planned for the analysis of sec-
ondary efficacy outcomes, with the alpha level 
split equally between KCCQ score and NYHA class, 
followed by the renal composite outcome. Con-
fidence intervals for the secondary and exploratory 
efficacy outcomes have not been adjusted for mul-
tiplicity, and therefore inferences drawn from these 
intervals may not be reproducible. Additional in-
formation regarding the statistical analysis is pro-
vided in the Supplementary Appendix.
R esult s
Enrollment, Randomization, and Follow-up
From July 18, 2014, through December 16, 2016, 
we screened 10,359 patients at 848 centers in 43 
countries (Fig. 1). A total of 4822 patients were 
randomly assigned to receive either sacubitril–
valsartan or valsartan. A total of 26 patients were 
excluded from all efficacy analyses because they 
had been enrolled at a site that was closed for 
major violations of Good Clinical Practice, so 4796 
patients were included in the efficacy analysis. 
At the end of the trial (April 30, 2019), fatal and 
nonfatal outcomes were known for all but 7 pa-
tients who had withdrawn consent and 2 patients 
who were lost to follow-up.
The characteristics of the patients at baseline 
were balanced between the two treatment groups, 
except for small differences in ischemic cause of 
heart failure and mineralocorticoid-receptor an-
tagonist use (Table 1). The median duration of 
follow-up was 35 months (interquartile range, 
30 to 41) in each group.
Outcomes
There were 894 primary events (690 hospitaliza-
tions for heart failure and 204 deaths from cardio-
vascular causes) in 526 patients in the sacubitril–
valsartan group and 1009 primary events (797 
hospitalizations for heart failure and 212 deaths 
from cardiovascular causes) in 557 patients in the 
valsartan group (rate ratio, 0.87; 95% confidence 
interval [CI], 0.75 to 1.01; P = 0.06) (Table 2 and 
Fig. 2). Because this difference did not meet the 
predetermined level of statistical significance, sub-
sequent analyses were considered to be explor-
atory. Components of the primary outcome are 
shown in Table 2. The prespecified sensitivity 
analyses of the primary outcome are shown in 
Tables S2 and S3 in the Supplementary Appendix.
The primary outcome in the 12 prespecified 
subgroups is shown in Figure 3. In a multivari-
able model that accounted for all potential inter-
actions and that used continuous measures when 
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appropriate, there was suggestion of heterogene-
ity of treatment effect with possible benefit in 
patients with lower ejection fraction and in wom-
en (Table S4 in the Supplementary Appendix).
Between baseline and month 8, there was a 
mean decrease in the KCCQ clinical summary 
score of 1.6 points in the sacubitril–valsartan 
group and 2.6 points in the valsartan group 
Figure 1. Screening, Randomization, and Follow-up.
The median duration of the valsartan run-in phase was 15 days (interquartile range, 12 to 22). One patient complet-
ed the valsartan run-in phase and underwent randomization without entering the sacubitril–valsartan run-in phase. 
The median duration of the sacubitril–valsartan run-in phase was 19 days (interquartile range, 15 to 23). One pa-
tient completed screening and entered the sacubitril–valsartan run-in phase without having entered the valsartan 
run-in phase.
4822 Underwent randomization
10,359 Patients were assessed for eligibility
4612 Were ineligible
4308 Did not meet entry criteria
259 Withdrew or were withdrawn by guardian
45 Had other reason
5746 Entered valsartan run-in phase
541 Discontinued
340 Had adverse event
98 Withdrew or were withdrawn by guardian
62 Had protocol deviation
41 Had other reason
384 Discontinued
262 Had adverse event
37 Withdrew or were withdrawn by guardian
49 Had protocol deviation
36 Had other reason
5205 Entered sacubitril–valsartan run-in phase
2419 Were assigned to receive
sacubitril–valsartan
2403 Were assigned to receive
valsartan
12 Were from one site 
prematurely closed to trial
on June 27, 2017, owing
to major Good Clinical
Practice violation
14 Were from one site 
prematurely closed to trial
on June 27, 2017, owing
to major Good Clinical
Practice violation
2407 Were included in sacubitril–valsartan
group
2402 Had known vital status
5 Had unknown vital status
2389 Were included in valsartan group
2385 Had known vital status
4 Had unknown vital status
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(between-group difference, 1.0 point; 95% CI, 
0.0 to 2.1). A higher percentage of patients in 
the sacubitril–valsartan group than in the val-
sartan group had an improvement of 5 or more 
points in the KCCQ clinical summary score 
(33.0% vs. 29.6%; odds ratio, 1.30; 95% CI, 
1.04 to 1.61). In the sacubitril–valsartan group, 
15.0% of the patients had an improvement in 
NYHA class at 8 months, 76.3% had no change, 
and 8.7% had a worse NYHA class, as compared 
with 12.6%, 77.8%, and 9.6%, respectively, in the 
valsartan group (odds ratio for improvement, 
1.45; 95% CI, 1.13 to 1.86). Worsening renal 
function occurred in 33 patients (1.4%) in the 
sacubitril–valsartan group and in 64 patients 
(2.7%) in the valsartan group (hazard ratio, 0.50; 
95% CI, 0.33 to 0.77). Death from any cause 
occurred in 342 patients (14.2%) in the sacubitril–
valsartan group and in 349 patients (14.6%) in 
the valsartan group (hazard ratio, 0.97; 95% CI, 
0.84 to 1.13).
Safety
After randomization, 610 patients (25.3%) in the 
sacubitril–valsartan group and 638 (26.7%) in 
the valsartan group discontinued the trial drug 
for reasons other than death, and 370 patients 
(15.4%) in the sacubitril–valsartan group and 
387 (16.2%) in the valsartan group discontinued 
the trial drug because of an adverse event. At the 
final visit, among the patients who were continu-
ing therapy, 82.0% in sacubitril–valsartan group 
were taking the target dose, as compared with 
85.1% in the valsartan group.
Patients in the sacubitril–valsartan group 
were more likely to have hypotension but less 
likely to have increases in the creatinine and 
potassium levels than those in the valsartan 
group (Table 3). The mean systolic blood pres-
sure at 8 months was 4.5 mm Hg (95% CI, 3.6 to 
5.4) lower in the sacubitril–valsartan group 
than in the valsartan group, but this difference 
was not correlated with the potential treatment 
effect (Fig. S1 and Table S2 in the Supplementary 
Appendix). Confirmed angioedema after random-
ization occurred in 14 patients in the sacubitril–
valsartan group and in 4 patients in the valsar-
tan group; no patients had airway compromise. 
The most frequent serious adverse events and 
adverse events are summarized in Tables S5 
and S6, respectively, in the Supplementary Ap-
pendix.
Discussion
In this trial involving patients with heart failure 
and preserved left ventricular ejection fraction, 
we compared treatment with sacubitril–valsartan 
with treatment with valsartan alone. The primary 
composite outcome of total hospitalizations for 
heart failure and death from cardiovascular causes 
did not differ significantly between the two groups. 
The findings from nine prespecified supportive 
and sensitivity analyses were consistent with those 
from the primary analysis.
There were fewer primary outcome events with 
sacubitril–valsartan than with valsartan, and an 
analysis of investigator-reported primary outcomes 
suggested a benefit of this therapy. There was a 
modest, although statistically nonsignificant, low-
er rate of hospitalizations for heart failure with 
sacubitril–valsartan than with valsartan and no 
significant difference in the risk of death from 
cardiovascular causes. Of four prespecified sec-
ondary outcomes, which were considered to be 
exploratory, the change in the NYHA class from 
baseline to month 8 and the occurrence of a de-
cline in renal function favored sacubitril–valsartan 
over valsartan. Sacubitril–valsartan was associated 
with a higher incidence of hypotension and angio-
edema but a lower incidence of elevated serum 
creatinine or potassium levels than valsartan.
Patients with heart failure and preserved ejec-
tion fraction are phenotypically heterogeneous,15 
and our data raise the possibility of a differential 
treatment effect in the broad population studied. 
Of the 12 prespecified subgroups, 2 showed pos-
sible heterogeneity of treatment effect, with a sug-
gestion of benefit in patients with an ejection 
fraction in the lower part (45 to 57%) of the range 
studied and in women, who represent a high 
proportion of patients with heart failure with 
preserved ejection fraction and who were well 
represented in this trial. The potential benefit of 
sacubitril–valsartan in patients with an ejection 
fraction at or below the median has biologic plau-
sibility. Several post hoc analyses of previous tri-
als have shown that other treatments that were 
efficacious in patients with heart failure and re-
duced ejection fraction may also benefit patients 
with left ventricular ejection fraction in the 
range of 40 to 55%, who often have subtle sys-
tolic dysfunction and are at higher risk for hos-
pitalization for heart failure.16-20 Our findings 
should also be considered in the context of the 
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on February 11, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;17 nejm.org October 24, 20191614
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
positive PARADIGM-HF trial,9 which had nearly 
identical entry criteria apart from a lower ejection 
fraction. Other diseases, such as amyloid cardio-
myopathy, may account for the reduced respon-
siveness with higher ejection fraction.21 The pres-
ent data suggest that patients with a mildly 
reduced ejection fraction may have a response to 
sacubitril–valsartan and possibly other therapies 
that improve outcomes in patients with heart 
failure and a more markedly reduced ejection 
fraction (≤40%).
We tested sacubitril–valsartan against an ac-
Characteristic
Sacubitril–Valsartan 
(N = 2407)
Valsartan 
(N = 2389)
Age — yr 72.7±8.3 72.8±8.5
Female sex — no. (%) 1241 (51.6) 1238 (51.8)
Race — no. (%)†
White 1963 (81.6) 1944 (81.4)
Black 52 (2.2) 50 (2.1)
Asian 297 (12.3) 310 (13.0)
Other 95 (4.0) 85 (3.6)
Geographic region — no. (%)
North America 288 (12.0) 271 (11.3)
Latin America 191 (7.9) 179 (7.5)
Western Europe 699 (29.0) 691 (28.9)
Central Europe 856 (35.6) 859 (36.0)
Asia–Pacific or other 373 (15.5) 389 (16.3)
Systolic blood pressure — mm Hg‡ 130.5±15.6 130.6±15.3
Heart rate — beats/min‡ 70.6±12.3 70.3±12.2
Body-mass index§ 30.2±4.9 30.3±5.1
Serum creatinine — mg/dl‡ 1.1±0.3 1.1±0.3
Estimated GFR — ml/min/1.73 m2 63±19 62±19
Clinical features of heart failure
Ischemic cause — no. (%) 899 (37.4) 824 (34.5)
Left ventricular ejection fraction — % 57.6±7.8 57.5±8.0
Median NT-proBNP (interquartile range) — pg/ml 904 (475–1596) 915 (453–1625)
NYHA functional class at randomization — no. (%)‡
I 73 (3.0) 64 (2.7)
II 1866 (77.5) 1840 (77.0)
III 458 (19.0) 474 (19.8)
IV 8 (0.3) 11 (0.5)
Missing data 2 (0.1) 0
Medical history — no. (%)
Hypertension 2304 (95.7) 2280 (95.4)
Diabetes 1046 (43.5) 1016 (42.5)
Atrial fibrillation or flutter 775 (32.2) 777 (32.5)
Stroke 266 (11.1) 242 (10.1)
Hospitalization for heart failure 1135 (47.2) 1171 (49.0)
Myocardial infarction 561 (23.3) 522 (21.9)
Table 1. Characteristics of the Patients at Baseline.*
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Characteristic
Sacubitril–Valsartan 
(N = 2407)
Valsartan 
(N = 2389)
Treatment — no. (%)
Diuretic agent at randomization 2294 (95.3) 2291 (95.9)
ACE inhibitor or ARB at screening 2074 (86.2) 2065 (86.4)
Mineralocorticoid-receptor antagonist at randomization 592 (24.6) 647 (27.1)
Beta-blocker at randomization 1922 (79.9) 1899 (79.5)
*  Plus–minus values are means ±SD. The characteristics of the patients at baseline were balanced between the two treat-
ment groups, except for small differences in ischemic cause of heart failure and mineralocorticoid-receptor antagonist 
use. Data were missing for the following characteristics: systolic blood pressure (for 1 patient in the valsartan group), 
heart rate (for 1 in the valsartan group), body-mass index (for 1 in the sacubitril–valsartan group), creatinine level (for  
1 in the valsartan group), ischemic cause of heart failure (for 1 patient in the sacubitril–valsartan group), N-terminal 
pro–B-type natriuretic peptide (NT-proBNP) level (for 19 patients in the sacubitril–valsartan group and 20 in the valsar-
tan group), and atrial fibrillation or flutter status (for 6 and 10, respectively). All other baseline data are complete un-
less otherwise noted. Percentages may not total 100 because of rounding. To convert the values for creatinine to micro-
moles per liter, multiply by 88.4. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, GFR 
glomerular filtration rate, and NYHA New York Heart Association.
†  Race was reported by the patient.
‡  This characteristic was measured at the randomization visit instead of at the screening visit.
§  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. (Continued.)
Outcome
Sacubitril–Valsartan 
(N = 2407)
Valsartan 
(N = 2389)
Ratio or Difference 
(95% CI)
Primary composite outcome and components
Total hospitalizations for heart failure and death from  
cardiovascular causes†
RR, 0.87 (0.75–1.01)
Total no. of events 894 1009
Rate per 100 patient-yr 12.8 14.6
Total no. of hospitalizations for heart failure 690 797 RR, 0.85 (0.72–1.00)
Death from cardiovascular causes — no. (%) 204 (8.5) 212 (8.9) HR, 0.95 (0.79–1.16)
Secondary outcomes
Change in NYHA class from baseline to 8 mo —  
no./total no. (%)
OR, 1.45 (1.13–1.86)
Improved 347/2316 (15.0) 289/2302 (12.6)
Unchanged 1767/2316 (76.3) 1792/2302 (77.8)
Worsened 202/2316 (8.7) 221/2302 (9.6)
Change in KCCQ clinical summary score at 8 mo‡ −1.6±0.4 −2.6±0.4 Difference, 1.0 (0.0–2.1)
Renal composite outcome — no. (%)§ 33 (1.4) 64 (2.7) HR, 0.50 (0.33–0.77)
Death from any cause — no. (%) 342 (14.2) 349 (14.6) HR, 0.97 (0.84–1.13)
*  Plus–minus values are means ±SD. Confidence intervals for secondary and exploratory efficacy outcomes have not been adjusted for multi-
plicity, and therefore inferences drawn from these intervals may not be reproducible. HR denotes hazard ratio, OR odds ratio, and RR rate 
ratio.
†  Total hospitalizations for heart failure included first and recurrent events. The primary analysis was based on the model of Lin et al.,13 and 
the composite outcome was adjudicated.
‡  Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores range from 0 to 100, with higher scores indicating fewer symp-
toms and physical limitations.
§  The renal composite outcome was defined as death from renal failure, end-stage renal disease, or a decrease in the estimated glomerular 
filtration rate of 50% or more from baseline.
Table 2. Primary and Secondary Outcomes.*
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Figure 2. Time-to-Event Curves for Primary Composite Outcome and Its Components.
Panel A shows Ghosh–Lin curves for the primary composite outcome of total hospitalizations for heart failure and 
death from cardiovascular causes, Panel B Ghosh–Lin curves for total hospitalizations for heart failure, and Panel C 
Kaplan–Meier curves for death from cardiovascular causes. Insets show the same data on an enlarged y axis.
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Figure 3. Primary Outcome in Prespecified Subgroups.
The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. 
Race was reported by the patient. New York Heart Association (NYHA) class may have changed between screening 
and randomization. Additional information is provided in Table S4 in the Supplementary Appendix. The diamond indi-
cates the overall effect, the size of the boxes is proportional to the number of patients in the subgroup, and arrows in-
dicate that the upper or lower boundary of the confidence interval is off the scale. ACE denotes angiotensin-converting 
enzyme, GFR glomerular filtration rate, and NT-proBNP N-terminal pro–B-type natriuretic peptide.
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tive comparator, valsartan, because most patients 
were receiving a renin–angiotensin system inhibi-
tor before enrollment, which made a placebo-
controlled trial impractical. Nevertheless, the 
potential benefit of angiotensin-receptor block-
ers in patients with heart failure with preserved 
ejection fraction (suggested in trials such as the 
Candesartan in Heart Failure — Assessment of 
Reduction in Mortality and Morbidity [CHARM-
Preserved] trial5) may have contributed to the 
smaller-than-anticipated treatment difference be-
tween groups.17 We cannot rule out the possibil-
ity that the run-in period may have influenced 
our results by excluding higher-risk patients and 
patients who could not take the trial drugs be-
cause of side effects.
We did not find a significant benefit of sacu-
bitril–valsartan in patients with heart failure 
with preserved ejection fraction with respect to 
the primary composite outcome of total hospi-
talizations for heart failure and death from car-
diovascular causes. In the context of known 
benefit of this treatment in patients with heart 
failure and left ventricular systolic dysfunction, 
and with the suggestion of a differential effect 
of sacubitril–valsartan in our trial in relation to 
left ventricular ejection fraction, future research 
should focus on the potential role of angiotensin 
receptor–neprilysin inhibition in patients with 
heart failure and ejection fraction that is below 
normal but not frankly reduced.22,23
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Event
Sacubitril–Valsartan 
(N = 2407)
Valsartan 
(N = 2389) P Value
Hypotension with systolic blood pressure <100 mm Hg 
— no. (%)
380 (15.8) 257 (10.8) <0.001
Elevated serum creatinine — no. (%)
≥2.0 mg/dl 261 (10.8) 328 (13.7) 0.002
≥2.5 mg/dl 97 (4.0) 109 (4.6) 0.36
≥3.0 mg/dl 38 (1.6) 40 (1.7) 0.79
Elevated serum potassium — no./total no. (%)
>5.5 mmol/liter 316/2386 (13.2) 361/2367 (15.3) 0.048
>6.0 mmol/liter 75/2386 (3.1) 101/2367 (4.3) 0.04
Angioedema — no. (%) 14 (0.6) 4 (0.2) 0.02
Liver-related adverse event — no. (%) 151 (6.3) 178 (7.5) 0.11
Table 3. Adverse Events during Randomized Treatment.
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